Samuel Meignan

9PUBLICATIONS
67CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 29, 2025
Novel Diffuse Midline Glioma-on-Chip Recapitulating Tumor Biophysical Microenvironment to Assess the Heterogeneity of Response to Therapies.

Lisa Terrassoux, Calypso Hazard, Agathe Laratte

|May 17, 2023
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.

Evangeline R Jackson, Ryan J Duchatel, Dilana E Staudt

|Nov 11, 2022
Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.

Delphine Hudry, Solenn Le Guellec, Samuel Meignan

|Oct 14, 2022
A Bloody Conspiracy- Blood Vessels and Immune Cells in the Tumor Microenvironment.

Lisa Terrassoux, Hugo Claux, Salimata Bacari

|Nov 13, 2021
H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines.

Andria Rakotomalala, Quentin Bailleul, Clara Savary

|Jul 02, 2021
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.

Marie Winter, Samuel Meignan, Pamela Völkel

Pageof 2

Frequent Collaborators

3 joint publications

Alessandro Furlan

3 joint publications

Xuefen Le Bourhis

3 joint publications

Eddy Pasquier

2 joint publications

Dilana E Staudt